Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 22, 2026, titled "Zydus launches the world s first biosimilar of Nivolumab, Tishtha , in India to treat multiple cancers".
Zydus Lifesciences Limited Press Release Jan 22 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced the launch of Tishtha™, the world's first biosimilar of Nivolumab, in India to treat multiple cancers. This new immunotherapy aims to reduce treatment costs significantly, making it more accessible to patients. The launch is expected to benefit a large number of patients, enhancing their access to advanced cancer care.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jan 15 2026
- Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.
- Press Release Jan 13 2026
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO(R), an Interchangeable Biosimilar to Lucentis(R)
- Press Release Dec 23 2025
Later from Zydus Lifesciences
- Press Release Jan 23 2026
- Press Release Feb 04 2026
- Press Release Feb 06 2026
- Press Release Feb 09 2026
- Press Release 10-02-2026 NewspaperPublication10022026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences